Kentaro Tajima - Search Results

Year	Number of Results
2019	1
2021	1
2022	3
2023	1
2024	1

1

Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan.

Moribe T, Xu L, Tajima K, Yonemoto N. Moribe T, et al. Among authors: tajima k. Future Oncol. 2023 Jun;19(19):1343-1356. doi: 10.2217/fon-2022-1314. Epub 2023 May 22. Future Oncol. 2023. PMID: 37212792 Free article.

2

Validity of Administrative Data for Identifying Birth-Related Outcomes with the End Date of Pregnancy in a Japanese University Hospital.

Tajima K, Ishikawa T, Matsuzaki F, Noda A, Morishita K, Inoue R, Iwama N, Nishigori H, Sugawara J, Saito M, Obara T, Mano N. Tajima K, et al. Int J Environ Res Public Health. 2022 Apr 16;19(8):4864. doi: 10.3390/ijerph19084864. Int J Environ Res Public Health. 2022. PMID: 35457731 Free PMC article.

3

Development and validation of claims-based algorithms to identify pregnancy based on data from a university hospital in Japan.

Tajima K, Ishikawa T, Noda A, Matsuzaki F, Morishita K, Inoue R, Iwama N, Nishigori H, Sugawara J, Saito M, Obara T, Mano N. Tajima K, et al. Curr Med Res Opin. 2022 Sep;38(9):1651-1654. doi: 10.1080/03007995.2022.2101817. Epub 2022 Jul 26. Curr Med Res Opin. 2022. PMID: 35833671

4

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.

Li RK, Tokunaga E, Adamchuk H, Vladimirov V, Yanez E, Lee KS, Bondarenko I, Vana A, Hilton F, Ishikawa T, Tajima K, Lipatov O. Li RK, et al. Among authors: tajima k. BioDrugs. 2022 Jan;36(1):55-69. doi: 10.1007/s40259-021-00513-7. Epub 2022 Feb 8. BioDrugs. 2022. PMID: 35133617 Free PMC article. Clinical Trial.

5

Real-world anticancer medications for reproductive-age women with breast cancer by using a claims database in Japan.

Tajima K, Tsuchiya M, Ishikawa T, Obara T, Mano N. Tajima K, et al. Future Oncol. 2021 May;17(15):1907-1921. doi: 10.2217/fon-2020-1053. Epub 2021 Feb 24. Future Oncol. 2021. PMID: 33625252 Free article.

6

Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.

Hara F, Tajima K, Tanabe K. Hara F, et al. Among authors: tajima k. Future Oncol. 2019 Apr;15(12):1353-1361. doi: 10.2217/fon-2018-0957. Epub 2019 Feb 15. Future Oncol. 2019. PMID: 30767568 Free article.

7

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.

Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: tajima k. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year